Nuvectis Pharma (NVCT) Q4 2025 earnings summary

Executive summary

• Achieved significant progress in the NXP900 development program, with multiple clinical studies enrolling and additional combinations planned for 2026.

• Cash position strengthened by a public offering and at-the-market facility, supporting operations into the second half of 2027.

Financial highlights

• Cash and cash equivalents rose to $31.6 million as of December 31, 2025, up from $18.5 million a year earlier.

• Net loss for 2025 was $26.4 million, compared to $19.0 million in 2024, reflecting increased R&D and G&A expenses.

• Research and development expenses increased to $18.2 million, up $5.3 million year-over-year.

• General and administrative expenses rose to $9.4 million, up $2.5 million year-over-year.

• Finance income was $1.1 million, up from $0.8 million in 2024.

Outlook and guidance

• Anticipates multiple data readouts from the NXP900 Phase 1b program in 2026.

• Current cash position expected to fund operations through key milestones and into the second half of 2027.